Showing results (41-50 of 52) with videos related to
Sort By:
Pageof 6
Breast Cancer (Tokyo, Japan)|December 9, 2023
Prevalent landscape of tumor genomic alterations of luminal B1 breast cancers using a comprehensive genomic profiling assay in TaiwanBo-Fang Chen, Yi-Fang Tsai, Pei-Ju Lien, et al.The Oncologist|July 12, 2019
Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal CancerMing-Huang Chen, Shih-Ching Chang, Pei-Ching Lin, et al.Annals of Surgical Oncology|February 28, 2022
Prevalence of Tumor Genomic Alterations in Homologous Recombination Repair Genes Among Taiwanese Breast CancersChi-Cheng Huang, Yi-Fang Tsai, Chun-Yu Liu, et al.Translational Oncology|September 15, 2023
Correlation of an immune-related 8-gene panel with pathologic response to neoadjuvant chemotherapy in patients with primary breast cancersLing-Ming Tseng, Chi-Cheng Huang, Yi-Fang Tsai, et al.Breast Cancer Research : BCR|December 30, 2025
Circulating T-cell receptor repertoire and clinicopathological correlations in breast cancer patients: immune repertoire analysis from the VGH-TAYLOR studyLing-Ming Tseng, Chi-Cheng Huang, Ji-Lin Chen, et al.Breast Cancer Research : BCR|December 15, 2023
Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR studyHan-Fang Cheng, Yi-Fang Tsai, Chun-Yu Liu, et al.Cancers|September 28, 2023
Concordance of Targeted Sequencing from Circulating Tumor DNA and Paired Tumor Tissue for Early Breast CancerChi-Cheng Huang, Yi-Fang Tsai, Chun-Yu Liu, et al.Experimental Cell Research|May 20, 2023
Regorafenib induces damage-associated molecular patterns, cancer cell death and immune modulatory effects in a murine triple negative breast cancer modelLing-Ming Tseng, Ka-Yi Lau, Ji-Lin Chen, et al.Cancer Treatment and Research Communications|March 26, 2025
A retrospective study to investigate the prevalence and describe the clinicopathological characteristics, treatments, and outcomes of HER2-low Breast Cancer in TaiwanKuo-Ting Lee, Po-Hsiang Huang, Chih-Yi Hsu, et al.Journal for Immunotherapy of Cancer|April 3, 2020
PRKDC: new biomarker and drug target for checkpoint blockade immunotherapyKien Thiam Tan, Chun-Nan Yeh, Yu-Chan Chang, et al.Pageof 6